Corcept Therapeutics (CORT) Misses Q1 EPS by 9c
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $111.62 -1.05%
Revenue Growth %: +54.6%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +54.6%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of ($0.06), $0.09 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $27.6 million versus the consensus estimate of $25.53 million.
GUIDANCE:
Corcept Therapeutics sees FY2017 revenue of $125-135 million, versus the consensus of $124 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- lululemon athletica (LULU) Tops Q2 EPS by $1.10, Cuts Guidance
- Dell’s earning report was bullish for Intel CPU demand, analyst says
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
